Neurovia
2013
FOUNDED
OOB
STATUS
Out of Business
LATEST DEAL TYPE
Description
Developer of therapies designed to offer treatment for neurological disorders. The company's therapies have developed a selective thyromimetic agent for the treatment of X-linked adrenoleukodystrophy, enabling X-ALD patients to get treatment for their rare genetic disease.
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
- 1700 Owens Street
- Suite 525
- San Francisco, CA 94158
- United States
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore Neurovia’s full profile, request a free trial.
Neurovia Valuation and Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Out of Business | 01-Nov-2018 | 000.00 | Completed | Out of Business | ||
| 1. Early Stage VC (Series A) | 25-May-2017 | 000.00 | 000.00 | 000.00 | Completed | Clinical Trials - Phase 1 |
Neurovia Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|---|---|---|---|---|---|---|---|
| Series A | 00,000,000 | 00.000000 | 00.00 | 00 | 00 | 00 | 00 | 00.000 |
Neurovia Competitors (17)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Intarcia Therapeutics | Venture Capital-Backed | Boston, MA | 000 | 00.000 | 0000000000 0 | 00.000 |
| 00000000 | Accelerator/Incubator Backed | New York, NY | 00 | 000.00 | 0000000000 | 000.00 |
| 000000000 | Formerly VC-backed | South San Francisco, CA | 00000 | 000.00 | 00000000000 | |
| 0000000 | Venture Capital-Backed | Cambridge, United Kingdom | 00 | 00.000 | 0000000000 0 | 00.000 |
| 000000 000 | Venture Capital-Backed | New Haven, CT | 0 | 00.00 | 00000000000 | 00.00 |